Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma

NCT06441019 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab

Interventions

DRUG: HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab

Sponsor

Fudan University